On September 4, 2020 Following a successful $3 million seed funding round earlier this month, University of California, San Diego spinout Micronoma reported that it is commercializing a blood-based diagnostic assay that identifies a patient’s organ microbiome signature to potentially detect early-stage cancers (Press release, Micronoma, SEP 4, 2020, View Source [SID1234578343]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!